Denying Preventive Treatment Can Have Life-threatening Consequences
There we were, in the same hospital where my son Deskin’s twin brother, Jake, passed away at just two days old. Fear washed over me. I looked at my husband, “How did we end up back here?” I asked.
Another State Calls it Quits with Pharmacy Benefit Managers
Michigan Medicaid has a message for the state’s pharmacy benefit managers: This isn’t working.
Hepatitis C Rates Spike Among Pregnant Women
New data show a startling trend: Rates of hepatitis C among pregnant women have significantly increased.
Making Step Therapy Safe for Patients
A new bill introduced in the U.S. Senate would curb the health plan practice of requiring patients to try and fail an insurer-preferred drug before getting the one their doctor prescribed.
ICER Fumbles Rheumatoid Arthritis Report
The controversial Institute for Clinical and Economic Review has done something unprecedented: admitted it’s wrong.
“Why Care?” about Mental Illness
Patients and advocates for mental health will repeatedly answer the question “Why Care?” this week.
Can ICER Put a Value on Diabetes Management?
A new report from the Institute for Clinical and Economic Review says oral semaglutide treatment for people with Type 2 diabetes isn’t cost effective.
Uncertainty Plagues ICER Report on Type 2 Diabetes
Just one thing stands between some Type 2 diabetes patients and disease management: a dislike of needles.
Comments on ICER’s Type 2 Diabetes Report
Several methodological issues in the draft evidence report for oral semaglutide are likely biasing the results toward an overly restrictive cost-effectiveness result. These issues include: Not adequately accounting for the additional patient benefits that a once-daily oral formulation provides Not adequately accounting for the co-morbidities associated with Type 2 diabetes Underestimating the full costs Type […]
Federal Trade Commission Stands with Patients on “Bad Drug” Ads
For years, patients have been misled by “bad drug” ads that frighten them into abandoning their prescription medications. Now the Federal Trade Commission is speaking out.
